United States Government Owns patent for “Novel Human Ebola” Bundibugyo virus





According to public records the United States Centers for Disease Control and Prevention is the proud owner of patent No. CA2741523A1, a Human Ebola virus species best known as Ebola Bundibugyo virus.The new strain was produced from a Ugandan version of the virus that causes serious hemorrhagic fever in those who get infected.



Although it was first filed on October 24, 2008, the publication of the patent was done on April 29, 2010.

As published four people appear as the co-inventors of the virus: Jonathan S. Towner, Stuart T. Nichol, James A. Comer, Thomas G. Ksiazek and Pierre E. Rollin.

The list of applicants include the same four names in addition to The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services and Center For Disease Control.

According to the patent claim, the virus is:

1. an isolated Ebola virus comprising a nucleic acid molecule and a nucleotide sequence of a nucleotide sequence set forth in SEQ ID NOS: a nucleotide sequence hybridizing under stringent conditions to SEQ ID NOS: 1 or 10; or a nucleotide sequence of at least 70%-99% identity to the SEQ ID NOS: 1 or 10.

2. An isolated Ebola virus having Centers for Disease Control Deposit Accession No. 200706291.

“The invention is related to compositions and methods directed to a novel species of human Ebola (hEbola) virus.” That is, this a laboratory made strain of Ebola, not a naturally occurring or naturally mutated one.

According to the patent:

The present invention is based upon the isolation and identification of a new human Ebola virus species, EboBun. EboBun was isolated from the patients suffering from hemorrhagic fever in a recent outbreak in Uganda. The isolated virus is a member of the Filoviridae family, a family of negative sense RNA viruses. Accordingly, the invention relates to the isolated EboBun virus that morphologically and phylogenetically relates to known members filoviridae.

As per the information contained in the patent summary, it is stated that the EboBun is not the only “embodiment” that exists of this laboratory made strain. ” It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting,” reads the text.

As it was designed in a lab, the new strain (the EboBun) is more than 30% genetically distinct from other naturally occurring ebolavirus species. This means that the person or organization that holds the patent has complete control over the actual composition of the virus, which impedes third parties from actually working independently in an attempt to further understand the dangers that this new strain and the ones that served as originators for it, could present to the human population.

There is only one reason for supposed health agencies to get involved in the genetically engineering of dangerous viruses such as Ebola: the U.S. government and private business hope to create as many strains as possible and to offer the public as many vaccines as possible as the solution when one of the strains ‘escapes’ their laboratories, as it has happened before. They will, at the very least, hope to get billions of dollars in profits for the privilege that many will want to pay to access the alleged cure for a virus that may be able to jump from human to human, a characteristic that so far no naturally occurring strain has the ability to do.

Read the complete text of the patent here and make your own conclusions.

Many people like you read and support The Real Agenda News’ independent, journalism than ever before. Different from other news organisations, we keep our journalism accessible to all. The Real Agenda News is independent. Our journalism is free from commercial, religious or political bias. No one edits our editor. No one steers our opinion. Editorial independence is what makes our journalism different at a time when factual, honest reporting is lacking elsewhere. In exchange for this, we simply ask that you read, like and share all articles. This support enables us to keep working as we do.